Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.

NCT04930536 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04930536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
July 14, 2021
Completion date
May 2, 2023
Enrollment
103 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma